ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Combining p-tau217 and digital cognitive testing to predict cognitive decline.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
introductionWe investigated whether a multi-day learning curve (MDLC), derived from remote digital cognitive assessments over 1 week, adds prognostic value to plasma phosphorylated tau at threonine 217 (p-tau217) for predicting cognitive decline in cognitively unimpaired (CU) older adults.
methodsA total of 183 CU participants (mean age 73.3; 70% female) completed multi-day digital cognitive tests and provided plasma p-tau217. Linear mixed-effects models evaluated the independent and combined effects of baseline p-tau217 and MDLC on longitudinal cognitive decline over 2.5 years.
resultsAdding MDLC to p-tau217 significantly explained longitudinal cognitive trajectory beyond p-tau217 alone. Although higher p-tau217 and lower MDLC were independently associated with steeper decline, individuals with both risk factors declined the fastest. Notably, those with elevated p-tau217 level but preserved MDLC remained stable, distinguishing them from those at imminent risk. DISCUSSION: Combining digital learning metrics with plasma p-tau217 enables precise risk stratification. This approach identifies individuals most vulnerable to imminent decline, potentially enhancing screening for early preventive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.